Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France

BACKGROUND: Hereditary angioedema (HAE) is associated with a heavy burden of illness. OBJECTIVE: To evaluate use of lanadelumab in a French Authorization for Temporary Use (ATU) program. METHODS: ATU requests were made between October 12, 2018, and March 13, 2019; patients were followed through Sept...

Descripción completa

Detalles Bibliográficos
Autores principales: Fain, Olivier, Du-Thanh, Aurelie, Gobert, Delphine, Launay, David, Inhaber, Neil, Boudjemia, Karima, Aubineau, Magali, Sobel, Alain, Boccon-Gibod, Isabelle, Weiss, Laurence, Bouillet, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976389/
https://www.ncbi.nlm.nih.gov/pubmed/35365234
http://dx.doi.org/10.1186/s13223-022-00664-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976389/
https://www.ncbi.nlm.nih.gov/pubmed/35365234
http://dx.doi.org/10.1186/s13223-022-00664-4

Ejemplares similares